Are recommendations for the routine use of pharmacological thromboprophylaxis in total hip arthroplasty justified?
Amstutz
H C
HC
Joint Replacement Institute, Los Angeles, California 90007, USA.
Dorey
F J
FJ
D019644:Arthroplasty, Replacement, Hip; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D011183:Postoperative Complications / Q000401:mortality / Q000517:prevention & control*; D011292:Premedication; D015996:Survival Rate; D013923:Thromboembolism / Q000401:mortality / Q000517:prevention & control*; D015912:Thrombolytic Therapy
D005343:Fibrinolytic Agents